Literature DB >> 9591801

Follicular mucinosis presenting as an acneiform eruption: report of four cases.

G P Wittenberg1, L E Gibson, M R Pittelkow, R A el-Azhary.   

Abstract

Follicular mucinosis can be a primary idiopathic disease or a secondary disease associated with lymphoma. When it appears in childhood or adolescence, it is usually primary and self-limited. We describe four cases of follicular mucinosis occurring in early adulthood that have had protracted courses. Each presented as an unusual acneiform eruption. Two of the cases demonstrated a clonal genetic rearrangement of the T-cell receptor within the cutaneous lymphoid infiltrate, a finding not previously reported. Although its significance is not clear, the clonal lymphocytic expansion indicates a need for continued surveillance of these patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591801     DOI: 10.1016/s0190-9622(98)70473-6

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

Review 1.  Acneiform follicular mucinosis: an indolent follicular mucinosis variant unrelated to mycosis fungoides?

Authors:  S Geller; M Pulitzer; P L Myskowski
Journal:  Clin Exp Dermatol       Date:  2018-05-30       Impact factor: 3.470

2.  Scleromyxedematous Changes in a Patient With Long-Standing Mycosis Fungoides Who Progressed to Sézary Syndrome.

Authors:  Allen P Miraflor; Melissa P Pulitzer; Patricia L Myskowski; Shamir Geller
Journal:  Am J Dermatopathol       Date:  2019-11       Impact factor: 1.533

3.  A Case Report of a Cutaneous Mucinous Reaction Associated with Erlotinib Therapy Used in the Treatment of Metastatic Tonsillar Sinus Squamous Cell Carcinoma.

Authors:  Benjamin D Freemyer; Torres-Carlos A Cabala; Anisha B Patel
Journal:  J Immunother Precis Oncol       Date:  2019-12-13

4.  Alopecia mucinosa responding to antileprosy treatment: are we missing something?

Authors:  Rajiv Joshi; Vinay Gopalani
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.